Cryoablation + Immunotherapy + Lenvatinib: A New Triple Synergy in Biliary Cancer
In this article
A Cold Beginning Produces Hot Results
Cancers arising in the bile ducts, particularly intrahepatic cholangiocarcinoma (bile duct cancer within the liver), have long been among oncology's most resistant diseases. They are usually diagnosed late and recur frequently even after surgical removal. Until recently, options were very limited: throughout the 2010s, gemcitabine + cisplatin (GemCis) was the only standard.
But the past five years have begun to change this. TOPAZ-1 and KEYNOTE-966 brought immunotherapy into first-line treatment , achieving significant survival gains for the first time. Yet for progression after chemotherapy, second-line options remained a major gap, particularly for the majority without targetable alterations such as FGFR2 fusions or IDH1 mutations .
Published on 1 November 2025 in Nature Cancer , the CASTLE-01 study opens a new window. In advanced intrahepatic cholangiocarcinoma ( ICC), local treatment with cryoablation was tested as a way to awaken the immune system .
Cryoablationis a minimally invasive method increasingly used for tumors in the liver, kidneys and lungs. The idea is that freezing the tumor does more than destroy it: releasing tumor antigens can also create a natural vaccine-like immune effect.
This cold beginning produced hot results: CASTLE-01 showed that cryoablation followed by the anti-PD-1 antibody sintilimab and the VEGFR inhibitor lenvatinib could produce extraordinary responses even in ICC considered immunotherapy-resistant. Beyond proposing a treatment model, it offers a powerful message about cancer immunology's future: "The right combinations can make even silent tumors speak."
The Triple Combination: Cryoablation + Sintilimab + Lenvatinib
In this single-arm Phase 2 study in China, 28 patients with advanced or metastatic ICC who had previously received chemotherapy underwent cryoablation, followed within two weeks by the anti-PD-1 antibody sintilimab (200 mg every 3 weeks) and the VEGFR inhibitor lenvatinib (8–12 mg/day).
The Results Were Striking:
• Objective Response Rate (ORR): 75% (95% CI: 59–91%)
• Disease Control Rate (DCR): 100%
• Median Progression-Free Survival (mPFS): 16.8 months
• Median Overall Survival (mOS): 25.4 months
These results differ dramatically from conventional second-line FOLFOX, with PFS of 4 months and OS of 6 months . Treatment was well tolerated with manageable adverse effects, most commonly fatigue (68%) and hypertension (65%).
What Changed in the Tumor Microenvironment?
Beyond clinical success, a particularly notable feature was multi-omic mechanistic insight . Researchers analyzed liver biopsies before and after treatment using single-cell RNA sequencing (scRNA-seq) and imaging mass cytometry.
- Cryoablation increased dendritic cell activation and antigen presentation within tumor tissue.
- Sintilimab + lenvatinib enhanced migration of CD8⁺ PD1hi effector T cells into the tumor.
- A cold tumor microenvironment became hot and immunogenic .
- New CD8⁺ clones were observed replenishing the tumor from peripheral blood, a groundbreaking finding for long-term immune memory.
These findings provide unusually clear human evidence for the abscopal effect , in which local ablation triggers systemic immunity.
Clinical and Scientific Interpretation
CASTLE-01 demonstrates that even in immunotherapy-resistant cancers such as biliary tumors, the right combinations can reprogram immunity . Cryoablation destroys the tumor locally while training the immune system. Lenvatinib complements the synergy by remodeling vessels and facilitating T-cell entry.
This strategy could pave the way in ICC and other cold solid tumors for local-systemic combination therapies , potentially increasing durable responses even in groups considered untreatable.
Looking Ahead
The study signals an era of multilayered intervention. Systemic drugs and local treatments are complementary rather than competing approaches. In the near future, strategies targeting immune-vascular synchronization may do more than shrink tumors: they could durably transform immune memory.
Was this article helpful?
Your feedback helps us improve our content.
Reader comments
Share your comment
Your name and comment are published only after administrator approval. Your email address is never shown to visitors.
Be the first to comment.